Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20
- cell therapy
- Drug Discovery
- Drug delivery
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 363524
Licensee is developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer.
IPSCIO Record ID: 362483
– to generate and test Chimeric Antigen Receptor T-Cell Products solely for the Development, Regulatory Approval and Commercialization of Products containing such Chimeric Antigen Receptor I-Cell Products;
– to Develop and Commercialize Products in the Field in the Territory, provided that such Products are not Out-of-Scope Products; and
– to Commercialize the Chimeric Antigen Receptor for Products.
Product means any pharmaceutical product containing a Chimeric Antigen Receptor I-Cell Product developed by Licensor under a Research Program for which the JSC determines to file an IND or under a research program for which Licensee has exercised the Licensor Program Option, or, any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Licensee that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described above.
Allogcneic Cell Therapy means a genomically engineered patient-nonspecific T-cell expressing a Chimeric Antigen Receptor for delivery to a patient developed under the Allogeneic Cell Therapy Research Program satisfying the Allogeneic Cell Therapy Criteria.
Chimeric Antigen Receptor T-Cell Product means a T-Cell having a Chimeric Antigen Receptor, or, a T-cell under switch control having a Chimeric Antigen Receptor and any Activator Ligands or Exclusive Activator Ligands that are administered to control such T-cells irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such T-cell directed to a Target, or, an Allogeneic Cell Therapy, or, the Allogeneic Cell Therapy under switch control having a Chimeric Antigen Receptor directed to a Target and any Activator Ligands or Exclusive Activator Ligands that are administered to control such Allogeneic Cell Therapy irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such Allogeneic Cell Therapy, or, any component sold as a kit, such as a device, delivery system or therapy scheme for the above to modify such T-cell including one or more polypeptides or nucleic acids encoding a CAR.
Licensor Platform Technology means Licensors platform of research tools and technology necessary for Licensor to perform its tasks directed towards the design, identification, culturing, and/or production of genetically modified cells consistent with this Agreement, including without limitation the technology embodied in the Licensor Materials and the Licensor Patents, and specifically including without limitation the following of Licensors platform areas and capabilities
(3) DNA and RNA MOD engineering,
(4) protein engineering,
(5) transcription control chemistry,
(6) genome engineering,
(7) cell system engineering,
(8) Endometrial Regenerative Cells,
(9) the RheoSwitchE technology and RheoSwitch Therapeutic Systems, and
(10) MD Anderson CC Technologies.
IPSCIO Record ID: 262605
IPSCIO Record ID: 308262
The two co-lead product candidates are NKX101 and NKX019. NKX101 is designed to enhance the power of innate NK biology to detect and kill cancerous cells
IPSCIO Record ID: 372431
By this agreement, Licensee is obtaining a non-exclusive license to the Licensed Patents for use in the Field.
Licensor grants a non-exclusive sub license under the Licensed Patents for the Term of this Agreement to develop, have developed, make, have made, use, have used, import, offer for sale, have offered for sale, sell and have sold Licensed Products and Licensed Services.
CART-19 shall mean a chimeric antigen receptor T cell directed against CD-19.
Penn Construct shall mean a CART-19 that includes a 4-1 BB signaling domain and a CD3s signaling domain.
Patent No. 8,399,645, titled 'Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.'
IPSCIO Record ID: 346459
Licensed Patents shall mean Chimeric receptors with 4-1BB stimulatory signaling domain, and, shall specifically exclude 7,435,596 and 8,026,097 , and any other patent or patent application that claims priority to, or common priority with, or is a divisional, continuation, re-issue, renewal, reexamination, substitution or extension of any patent or patent application identified in clause (a) above that contains only claims directed to the expansion of natural killer NK cells.
Licensed Product shall mean any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under this Agreement. For the avoidance of doubt, as of the Effective Date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, as defined under this Agreement.
Penn Construct shall mean a CART- 19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.
Licensor is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
IPSCIO Record ID: 307594
The companies will partner to develop Licensorâ€™s next-generation bispecific antibody programs, epcoritamab (DuoBodyÂ®-CD3xCD20), DuoHexaBodyÂ®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensorâ€™s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licenseeâ€™s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensorâ€™s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licenseeâ€™s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBodyÂ® platform for generation of bispecific antibodies, the HexaBodyÂ® platform, which creates effector function enhanced antibodies, the HexElectÂ® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBodyÂ® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
IPSCIO Record ID: 136308
U.S. Patent Application USSN 62/237,835 – Therapeutic compounds and its uses
Patent relates to commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.
IPSCIO Record ID: 356954
an exclusive license, sublicenseable, under the Licensor know-how, solely after the end of the Restriction Period, to research, develop, make, have made, use, sell, offer for sale, and import Compounds in the Field in the Territory.
For the Research License, Licensor grants a perpetual, irrevocable, non-exclusive, non-sublicensable except to Third Party contractors and service providers performing for the benefit of Licensee, license under the Licensor Technology and Licensee Technology to make, import, and use but not to sell or offer for sale Compounds for internal research purposes only.
Licensor grants an option to obtain an exclusive, sublicense from Licensor to certain Patent Rights licensed to Licensor under the Georgia Regents Research Institute License Agreement or Lankcnau Institute for Medical Research License Agreements, to research, develop, make, have made, use, sell, offer for sale and import Compounds and Licensed Products in the Field in certain countries in the Territory.
Licensed Compound means NLG919 or any Next Generation Compound.
NLG919 means Licensorâ€™s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, as further described in IND 119045 or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.
Compound means a compound with a molecular weight of two thousand (2,000) Daltons or less], that hinds to and inhibits the activity of one or both of the 100 Target and TDO Target. with an IC50 of 1 ÂµMor less in the applicable Enzymatic Assay, and that is being researched, developed or commercialized to exert its influence through the inhibition of one or both of the IDO Target or TDO Target, including NLG919, but excluding Indoximod.
Enzymatic Assay means, with respect to the IDO Target, the assay described in IND 119045 Document PD0l-MRMP01 1-SP04-E248, and, with respect to the TDO Target. Enzymatic Assay shall also include an alternate means of detecting the products of the enzyme reactions or minor changes in the above enzyme assay protocols, as agreed upon by the JRC. Any IC50s of control compounds measured with an alternate assay format should fall within 3-fold of the assay method.
Indoximod means Licensorâ€™s proprietary small molecule IDO pathway inhibitor known as of the Execution Date as indoximod, or 1-methyl-D-tryptophan, or any, enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.
IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4, PD-1, and PD-L1 that represent potential breakthrough approaches to cancer therapy. The IDO pathway regulates immune response by suppressing T-cell activation which enables local tumor immune escape. Recent studies have demonstrated that the IDO pathway is active in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor draining lymph nodes whereby this pathway promotes peripheral tolerance to tumor associated antigens (TAAs). When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system. NewLink has a number of active programs directed at synthesizing inhibitors to the IDO pathway and additionally has discovered novel tryptophan-2,3-dioxygenase (TDO) specific inhibitors that are potential anti-cancer compounds which could function individually or in combination with IDO inhibition.
Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.
IPSCIO Record ID: 296898
IPSCIO Record ID: 344529
This amendment #2 adds that Licensed Products shall mean, when used in relation to A Third Party Agreement, any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under the Third Party Sublicense Agreement. For the avoidance of doubt, as of the Third Party Sublicense Agreement. effective date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, and,
Adds that Licensed Services shall mean, when used in relation to the Third Party Sublicense Agreement, any service using a Licensed Product.
Penn Construct shall mean a CART-19 that includes a 4-1BB signaling domain and a CD3~ signaling domain. CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.
Patent Rights are amended to read Patent Rights, when used in relation to the Third Party Sublicense Agreement, shall mean the patent and patent applications listed in the Third Party Sublicense Agreement; and specifically exclude 7,435,596 and 8,026,097.
Licensee is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the bodyâ€™s immune system to treat cancer. Chimeric antigen receptor (CAR) recognize and kill cancer cells.
IPSCIO Record ID: 65323
With respect to CNDO-109, the Company has exclusive rights to International Patent Application No. PCT/GB2006/000960 and all pending United States and foreign counterpart applications including granted U.S. Patents No. 8,257,970 and 8,637,308 and the corresponding national phase applications granted in Australia and India and filed in Canada, Europe and Japan, directed to the stimulation of NK cells and related CNDO-109 compositions and methods including methods for the treatment of cancer and other conditions. This patent family has been in-licensed on an exclusive basis from University. The CNDO-109 patent has an expiration date of January 2029 in the absence of any patent term extension. By way of an amendment to the license agreement with Unversity, we also have exclusive rights to International Application No. PCT/GB2010/051135 and all pending United States and foreign counterpart applications including pending United States Patent Application Serial No. 12/833,694 and the corresponding national phase applications filed in Europe, Brazil, China, Israel, Singapore and South Africa, directed to the preservation of activated NK cells and related compositions and methods. The CNDO-109 patents that may issue from the former patent family would expire in July 2030 in the absence of any patent term extension. The amendment includes rights to certain additional confidential technologies as well.
CNDO-109 is a compound that has been shown to activate NK cells. When activated, NK cells have the ability to differentiate between normal cells and cancer cells, and kill cancer cells by granzyme mediated lysis, a biochemical process whereby the NK cells directly kill cancer cells by destroying their cell membranes and structures.
IPSCIO Record ID: 318779
IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.
IRX-2 is produced under current good manufacturing practices, or cGMP, following stimulation of a specific population of human peripheral blood mononuclear cells (PMBC) using a specified mitogen. These cells consist of lymphocytes (T cells, B cells, NK cells) and monocytes. Cytokine production induced by the employed mitogen mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. PBMCs are obtained from FDA-licensed blood banks meeting all criteria for further human use.
The Licensee is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer.
IPSCIO Record ID: 184504
The original agreement entered into a broad, global alliance with the parties to discover, develop and commercialize novel immuno-therapeutics using the antibody platforms. The collaboration was initially focused on four CPM programs targeting GITR, OX40, TIM-3 and LAG-3, and in November 2015, was expanded by adding three novel undisclosed CPM targets.
GITR is an immune checkpoint agonist, one of a class of receptors that amplify the immune systemâ€™s response to cancer. GITR (glucocorticoid-induced TNFR-related protein) is a receptor expressed on select populations of T cells. Activation of GITR leads to a more powerful anti-tumor inflammatory response, increased production of inflammatory signaling molecules and increased resistance to immunosuppression.
OX40 (also known as CD134 and TNFRSF4), a member of the TNFR super-family, is an immune-response-enhancing receptor found on activated T cells. OX40 promotes proliferation of these activated T cells and prevents the immunosuppressive activity of inhibitory T cells. We believe that antibodies that activate OX40 may help increase immune system activity through both of these mechanisms. Furthermore, OX40 antibodies have the potential to work alone or in combination with other therapeutics. Combining with another agonist checkpoint antibody, which provides different, yet complementary signaling attributes may further augment anti-tumor responses.
IPSCIO Record ID: 332563
Under the terms of the agreement, Licensee will also be granted options to Licensorâ€™s TIGIT-targeted antibody and next generation engineered IL-2 cytokine for evaluation as potential combination therapies with toripalimab, as well as certain negotiation rights to two early-stage checkpoint inhibitor antibodies.
JS006, an antibody targeting TIGIT.
JS018, a next-generation engineered IL-2 cytokine
Two additional undisclosed early-stage novel immuno-oncology drug candidates.
JS006 is an antibody targeting TIGIT, a clinically validated immune inhibitory checkpoint. Anti-TIGIT antibodies have demonstrated synergistic anti-tumor activity in combination with anti-PD-1 antibodies.
JS018 is a next-generation engineered IL-2 cytokine designed to inhibit stimulation of regulatory T cells while retaining stimulatory activity on effector T cells and natural killer (â€œNKâ€) cells. The option to JS018 is exercisable prior to initiation of Phase 2 clinical development.
By this Collaboration, the Parties plan to file additional toripalimab BLAs with the FDA over the next three years for multiple rare and highly prevalent cancers, including non-small cell lung cancer (â€œNSCLCâ€).
IPSCIO Record ID: 257238
BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.
Target means a cell-surface antigen. The list of proprietary targets is epha2, alpha – V, and, beta-3.
BiTE molecules are designed to direct the bodyâ€™s cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.
Licensee's product candidates aim to efficiently redirect the patientâ€™s immune response to tumor cells either through the use of specific recombinant antibodies for the eradication of cancer cells, as is the case with adecatumumab, or through BiTE molecules, which target cancer cells for elimination by the patientâ€™s own T cells.
IPSCIO Record ID: 312594
In April 2020, the Court granted in part Licensorâ€™s motion and entered a final judgment awarding royalties on Licenseeâ€™s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.
Yescarta is a trademark of Licensee. Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patientâ€™s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.
IPSCIO Record ID: 246212
Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS
NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for antigen presentation, which is why they are called â€œnatural killers.â€
Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.
IPSCIO Record ID: 351110
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke.
IPSCIO Record ID: 336300
Licensee Product means (a) as it relates to a Licensee Target, other than an Additional Target, a CAR Product directed against such particular Licensee Target based upon or generated using the constructs or complexes for CAR Products generated in the conduct of the Preclinical Development Plan for such Licensee Target; and (b) as it relates to a Licensee Additional Target (if any) either a CAR Product or a TCR Product (but not both) directed against such Additional Target, based upon or generated using the constructs or complexes for CAR Products or TCR Products, as the case may be. generated in the conduct of the Preclinical Development Plan for such Additional Target. For clarity, upon Licensorâ€™s exercise of its option to obtain exclusive rights to an Licensor Optioned Target, Licensee Products shall exclude Licensor Optioned Products.
CAR Product means a pharmaceutical or biologic product containing an adoptive T cell expressing a CAR directed against a particular Target.
Licensee Target means a Target specified as a Licensee Target pursuant to this agreement (Target Selection) or any New Target selected by Licensee. For clarity, Licensee Target shall exclude any Removed Target. Licensee Target excludes any Licensor Optioned Target.
Target means an antigen expressed on or in a tumor cell.
The Parties will jointly create preclinical development plans through IND filing with the FDA for the research and development of CAR-based product candidates that target certain antigens expressed on the cell surface of various cancers.